- Home
- NNY vs MCRB Comparison
NNY vs MCRB Comparison
Compare NNY & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNY
- MCRB
- Stock Information
- Founded
- NNY 1987
- MCRB 2010
- Country
- NNY United States
- MCRB United States
- Employees
- NNY N/A
- MCRB N/A
- Industry
- NNY Investment Managers
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- NNY Finance
- MCRB Health Care
- Exchange
- NNY Nasdaq
- MCRB Nasdaq
- Market Cap
- NNY 156.0M
- MCRB 141.9M
- IPO Year
- NNY N/A
- MCRB 2015
- Fundamental
- Price
- NNY $8.01
- MCRB $0.37
- Analyst Decision
- NNY
- MCRB Hold
- Analyst Count
- NNY 0
- MCRB 5
- Target Price
- NNY N/A
- MCRB $4.00
- AVG Volume (30 Days)
- NNY 50.9K
- MCRB 1.3M
- Earning Date
- NNY 01-01-0001
- MCRB 05-07-2025
- Dividend Yield
- NNY 4.04%
- MCRB N/A
- EPS Growth
- NNY N/A
- MCRB N/A
- EPS
- NNY N/A
- MCRB 0.00
- Revenue
- NNY N/A
- MCRB N/A
- Revenue This Year
- NNY N/A
- MCRB N/A
- Revenue Next Year
- NNY N/A
- MCRB N/A
- P/E Ratio
- NNY N/A
- MCRB $474.36
- Revenue Growth
- NNY N/A
- MCRB N/A
- 52 Week Low
- NNY $7.58
- MCRB $0.46
- 52 Week High
- NNY $8.87
- MCRB $1.53
- Technical
- Relative Strength Index (RSI)
- NNY 34.09
- MCRB 28.34
- Support Level
- NNY $7.96
- MCRB $0.36
- Resistance Level
- NNY $8.11
- MCRB $0.67
- Average True Range (ATR)
- NNY 0.10
- MCRB 0.07
- MACD
- NNY -0.02
- MCRB -0.02
- Stochastic Oscillator
- NNY 31.25
- MCRB 2.71
About NNY Nuveen New York Municipal Value Fund
Nuveen New York Municipal Value Fund Inc is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from both regular federal and New York state income taxes, by investing primarily in a portfolio of municipal obligations issued by state and local government authorities within the state of New York or certain U.S. territories.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.